Naltrexone for opioid use disorders a review of clinical effectiveness, cost-effectiveness, and guidelines

The Food and Drug Administration in the U.S. approved naltrexone (XR-NTX) in 2010, however, in Canada extended-release naltrexone is only available through the Health Canada's Special Access Programme or for research. Given the relative novelty of XR-NTX, its effectiveness compared with oral na...

Full description

Bibliographic Details
Main Authors: Jahagirdar, Deepa, Wright, Mary-Doug (Author)
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health July 4, 2017, 2017
Edition:Version 1.0
Series:CADTH rapid response report: summary with critical appraisal
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 01836nam a2200253 u 4500
001 EB002000901
003 EBX01000000000000001163802
005 00000000000000.0
007 tu|||||||||||||||||||||
008 210907 r ||| eng
100 1 |a Jahagirdar, Deepa 
245 0 0 |a Naltrexone for opioid use disorders  |h Elektronische Ressource  |b a review of clinical effectiveness, cost-effectiveness, and guidelines  |c Deepa Jahagirdar, Mary-Doug Wright 
250 |a Version 1.0 
260 |a Ottawa (ON)  |b Canadian Agency for Drugs and Technologies in Health  |c July 4, 2017, 2017 
300 |a 1 PDF file (38 pages)  |b illustrations 
505 0 |a Includes bibliographical references 
700 1 |a Wright, Mary-Doug  |e [author] 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH rapid response report: summary with critical appraisal 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK525041  |3 Volltext 
082 0 |a 610 
520 |a The Food and Drug Administration in the U.S. approved naltrexone (XR-NTX) in 2010, however, in Canada extended-release naltrexone is only available through the Health Canada's Special Access Programme or for research. Given the relative novelty of XR-NTX, its effectiveness compared with oral naltrexone remains unclear, despite the potential for higher adherence. In addition, the clinical and cost effectiveness of both these options is relevant because having multiple treatment options can support stakeholders to treat opioid dependence. This review assesses the clinical effectiveness, cost-effectiveness and guidelines for oral and injectable naltrexone to treat opioid dependence to inform policy-making in Canada to address the increasing burden of opioid use disorders